TYK2 Inhibition in Paradoxical Psoriasis

Sponsor
Prof Curdin Conrad
Study ID
NCT06281106
Phase
PHASE2/PHASE3
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped and so far, no specific treatment for paradoxical psoriasis exists. This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a tablet taken by mouth once a day is superior compared to taking a placebo in treating paradoxical psoriasis.

Key Dates

First listed
Feb 28, 2024
Start date
Jun 20, 2024
Status verified
Mar 2025
Primary completion
Mar 20, 2025
Completion
Mar 20, 2025

Study Design

Enrollment
2 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 'Deucravacitinib'
    Deucravacitinib 6mg oral intake once daily for 4 weeks
  • Placebo Comparator: 'Placebo'
    Matching Placebo oral intake once daily for 4 weeks

Primary Outcome Measure

Paradoxical Psoriasis Investigator Global Assessment [ Time Frame: At Week 4 ]

Related Studies